Prescription Drug Cost Management Resources
As the 2017 state legislative sessions kick off, NASHP is continuing our work tracking legislative action on pharmaceutical pricing. Last year, states introduced dozens of bills on pharmaceutical prices, and the trend is expected to continue in 2017. A series of maps and accompanying chart summarize state legislation across six major “themes,” transparency, reimportation, pharmacy benefit managers, volume purchasing, research, and price regulation. These tools are the part of the NASHP Pharmacy Costs Workgroup, an ongoing project that looks beyond the strategies currently used in states to identify and develop new ideas, which address the growing problem of prescription drug costs.
NASHP’s Pharmacy Costs Work Group is comprised of state leaders from governors’ staff, state legislatures, Medicaid programs, public employees, attorney generals’ offices, state-based insurance exchanges, comptrollers’ offices, and corrections departments. The group aimed to find new approaches to limit pharmaceutical costs by examining the many levers state governments have as policymakers, regulators, and purchasers.
Interested in getting involved? Contact Corinne Alberts at firstname.lastname@example.org
- Susan Barrett, J.D., Executive Director, Green Mountain Care Board
- Burl Beasley, D.Ph., MPH, MS Pharm Clinical Pharmacist, Oklahoma Health Care Authority
- Robert Crittenden, M.D., Senior Policy Advisor to Governor, Washington
- James DeBenedetti Director, Plan Management Division, Covered California
- Rebekah Gee, Secretary, Dept. of Health and Hospitals, State of Louisiana
- Rory Griffin, Deputy Director, Arkansas Dept. of Corrections
- Richard Gottfried, Chair, Committee on Health, New York Assembly
- Emily Hancock, RPH, Phar. D., MPA Clinical Pharmacist, Indiana Dept. of Social and Family Services
- Nathan Johnson, Chief Policy Officer, Washington State Health Care Authority
- Heather Korbulic, Executive Director, Silver State Health Insurance Exchange
- Kevin Lembo, Comptroller, State of Connecticut
- Janet Mills, J.D., Attorney General, State of Maine
- Rebecca Pasternik-Ikard, Chief Executive Officer, Oklahoma Health Care Authority
- David Seltz, Executive Director, Massachusetts Health Care Commission
- Norman Thurston, Ph.D., Utah State Legislature
- Eileen Mallow, Deputy Director, WI Dept. of Employee Trust Funds
- Linda Wiant, Chief, Medical Assistance Plans, State of Georgia
NASHP’s Pharmacy Cost Workgroup is a diverse set of state leaders from across the nation, representing all perspectives in states – legislative and executive branch, Attorney’s General, Medicaid, Corrections and more, brought together to address growing concerns of rising drug prices. The aim of this group is to identify emerging strategies to address drug costs and to develop and test solutions. With support from the John and Laura Arnold Foundation and Kaiser Permante, the workgroup has developed background papers and engaged in deliberations about what states as purchasers, regulators and policymakers can do to address the trajectory of Rx prices. The result, “States and the Rising Costs of Pharmaceuticals: A Call to Action”, is a preliminary toolbox of options for state policymakers. NASHP is working with states to develop those options into practical, actionable solutions to address high cost prescription drug prices.
In this section you can access all the previous workgroup products including legislative tracking, background papers, policy proposals, and the model legislation.
- States and the Rising Cost of Pharmaceuticals: A Call to Action
This brief outlines 11 specific proposals ranging from regulatory interventions to more market-oriented approaches for states to consider when developing policies to help control rising pharmaceutical costs. The proposals focus on consumer protections, increasing oversight and price regulation and coordinating state purchasing power across public employees, Medicaid and Corrections
- State Legislative Action on Pharmaceutical Prices (Map)
As part of its work in pharmacy cost policy, NASHP tracks state legislation seeking to control the rising cost of prescription drugs. This series of maps summarize state legislation that has been introduced during the 2015-2016 legislative season. The six categories comprise the major “themes” seen in legislation.
- State Legislative Action on Pharmaceutical Prices (Chart)
As part of its work in pharmacy cost policy, NASHP tracks state legislation seeking to control the rising cost of prescription drugs. This chart summarize state legislation that has been introduced during the 2015-2016 legislative season. The six categories comprise the major “themes” seen in legislation
- States and Prescription Drugs: An Overview of State Programs to Rein in Costs
States are significant purchasers of health care for Medicaid, inmates in correctional facilities, and public employees. Despite considerable efforts to maintain affordability, drug pricing continues to vex state budgets. This paper provides an overview of current state programs to rein in drug costs.
- States and the Rising Cost of Pharmaceuticals: A Call to Action – Two Page Summary
This two page document gives an overview of the 11 policy proposals outlined in “States and the Rising Cost of Pharmaceuticals: A Call to Action.”
In this section please find registration and information for all upcoming webinars of the Pharmacy Cost Workgroup, as well as the recordings and slide decks of previous webinars.
States and the Rising Costs of Pharmaceuticals: A Call to Action, January 11th, 2017
- Lembo targets ‘skyrocketing’ drug prices January 24, 2017
- How can states tackle rising medication prices? January 11, 2017
- Interfaith investor coalition pushes shareholder resolutions on drug prices, October 24, 2016
- Politico Pulse mentioned the findings of the Pharmacy Costs Work Group, October 24, 2016
- Group looks at ways to rein prescription drug costs, October 19, 2016
- PAPs may be a lifeline, but they’re not the final answer, October 19, 2016
- Treat pharma as a utility, and 10 other ways states can lower drug prices, October 19, 2016
- Should drug costs be controlled by regulating industry as a public utility?, October 19, 2016
- Treat pharma as a utility, and 10 other ways states can lower drug prices, October 18, 2016
NASHP, with guidance from our Pharmacy Costs Workgroup, has developed a model legislation for states that wish to take a comprehensive approach to unlock the black box of prescription drug pricing and increase consumer awareness. States interested in this model legislation will have access to a legislator’s guide and additional background materials as they become available. Please contact email@example.com if you wish to receive this state-only material.